Xenetic Biosciences, Inc. (NASDAQ:XBIO)
| Market Cap | 5.02M-32.4% |
| Revenue (ttm) | 3.26M+33.3% |
| Net Income | -2.48M+19.7% |
| EPS | -1.19+40.5% |
| Shares Out | 2.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,492,329 |
| Open | 2.75 |
| Previous Close | 4.27 |
| Day's Range | 1.87 - 2.79 |
| 52-Week Range | 1.87 - 13.93 |
| Beta | 2.24 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About XBIO
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
$XBIO stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in XBIO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by XBIO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
XBIO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New XBIO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to XBIO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in XBIO
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $53.13K |
Estimated from each fund’s disclosed top holdings × AUM
XBIO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from XBIO’s recent data — informational, not investment advice